Characterization of omalizumab updosing patterns and predictive factors in chronic spontaneous urticaria: A prospective multicentric observational study.

Autor: Pierrard G; CHU Lille, University Lille, Service de Dermatologie, Lille, France., Bernier C; French Chronic Urticaria Study Group (GUS), Paris, France.; CHU Nantes, Service de Dermatologie, Nantes, France., Du-Thanh A; French Chronic Urticaria Study Group (GUS), Paris, France.; CHU Montpellier, Service de Dermatologie, Montpellier, France., Bara C; French Chronic Urticaria Study Group (GUS), Paris, France.; CHU Le Mans, Service de Dermatologie, Le Mans, France., Soria A; French Chronic Urticaria Study Group (GUS), Paris, France.; Sorbonne Université, Service de Dermatologie et d'Allergologie, Hôpital Tenon, Paris, France., Castelain F; French Chronic Urticaria Study Group (GUS), Paris, France.; CHU Besançon, Service de Dermatologie, Besançon, France., Boccon-Gibod I; French Chronic Urticaria Study Group (GUS), Paris, France.; CHU Grenoble, Service de Médecine Interne et Immunologie Clinique, Centre de Reference des Angiœdèmes, Grenoble, France., Hacard F; French Chronic Urticaria Study Group (GUS), Paris, France.; CHU Lyon, Service Allergologie et Immunologie Clinique, Lyon, France., Delaunay J; French Chronic Urticaria Study Group (GUS), Paris, France.; CHU Angers, Service de Dermatologie Angers, Angers, France., de Montjoye L; French Chronic Urticaria Study Group (GUS), Paris, France.; Department of Dermatology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium., Staumont-Salle D; CHU Lille, University Lille, Service de Dermatologie, Lille, France.; French Chronic Urticaria Study Group (GUS), Paris, France.; U1286 Inserm INFINITE Institute for Translational Research in Inflammation, Lille, France., Dezoteux F; CHU Lille, University Lille, Service de Dermatologie, Lille, France.; French Chronic Urticaria Study Group (GUS), Paris, France.; U1286 Inserm INFINITE Institute for Translational Research in Inflammation, Lille, France.
Jazyk: angličtina
Zdroj: Allergy [Allergy] 2024 Sep; Vol. 79 (9), pp. 2448-2457. Date of Electronic Publication: 2024 Jul 26.
DOI: 10.1111/all.16256
Abstrakt: Background: Limited information is available on the use of omalizumab (OMA) updosing since its introduction as a second-line therapy in chronic spontaneous urticaria (CSU) in 2014. Practical guidelines from health authorities are lacking, and the specific characteristics of patients requiring higher doses remain unknown. Our objectives were to characterize the patterns of OMA updosing (defined as changes in dose and/or injection intervals), to identify the predictive factors associated with updosing, and to improve CSU management.
Methods: We conducted a prospective, multicentric, real-life observational study, including patients diagnosed with CSU and starting OMA. The data were collected at 0, 3, 6, and 9 months. The primary endpoint was the frequency of OMA updosing at 3 months. The secondary endpoints included an analysis of updosed patients' profile, and an assessment of OMA efficacy and safety.
Results: We included 153 patients. Twenty percent of patients were updosed at 3 months, and 27% in total during the 9-month follow-up. Practitioners mainly chose to increase the frequency of injections (66%). At baseline, the updosed patients were more likely to have more severe CSU (UCT < 4, p < 0.030), a lower lymphocyte count (<2000/mm 3 , p = 0.037), and low IgE levels (<70 UI/mL, p = 0.024). The side effects of OMA were not more frequent after updosing.
Conclusion: One in five patient underwent updosing within just 3 months. OMA updosing is frequent in particular in cases of severe disease and low IgE blood levels.
(© 2024 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: